摘要
目的:探讨雌激素调节基因组蛋白脱乙酰基酶6(HDAC6)的表达与乳腺癌临床病理学参数、预后及辅助三苯氧胺(TAM)内分泌治疗疗效的关系,明确HDAC6对辅助内分泌治疗的指导地位。方法:采用免疫组化方法检测93例雌激素受体(ER)阳性原发乳腺癌HDAC6的表达,统计学分析其与临床病理学参数及预后的关系。结果:①原发ER(+)乳腺癌HDAC6的阳性表达为27.96%②HDAC6表达与临床分期、肿瘤大小密切相关,在肿瘤比较大、临床分期晚的患者中高表达(P<0.05),与患者年龄、月经状态、腋淋巴结转移数目、PR状态、CerbB-2状态无相关性。③HDAC6与ER(+)乳腺癌的生存期呈负相关,生存期大于10年组中HDAC6阳性率明显低于生存期小于10年组(P<0.05);Kaplan-Meiler分析表明HDAC6是预测DFS的预后因素。结论:在ER(+)乳腺癌HDAC6与生存期呈负相关,是预后差的指标,而且是预测ER阳性乳腺癌患者辅助内分泌治疗疗效的敏感指标。
Objective： To investigate the expression of estrogen-regulated genes HDAC6 in breast cancer and it＇s relation to the clinical manifestation, prognosis and the response of to adjuvant tamoxifen therapy, Methods： Immuno-staining for HDAC6 was performed on 93 paraffin-embedded specimens of ER （＋） primary breast cancer patients. Results： （1） Positive expression rate of HDAC6 in primary breast cancer was 27.96 % ; （2） Expression of HDAC6 was positively correlated with tumou size, clinical stage and the positive rate of HDAC6 expression in big tumors and the late of clinical stage was higher than other ones （P〈0.05）, It was not correlated with age, meno-pausal status, axillary lymph nodes, PR and CerbB-2, （3） The expression of HDAC6 was related with DFS （P〈0.05）. Kaplan-meier analysis demonstrated HDAC6 had independent influence on DFS, Conclusions： We detected the expression of HDAC6 in breast cancer, HDAC6 were related with DFS and may be markers for unfavorable prognosis in breast cancer, It can be used as a parameter additional to ER for better refinement and prediction of response to adjuvant tamoxifen therapy.
出处
《现代生物医学进展》
CAS
2008年第10期1897-1899,共3页
Progress in Modern Biomedicine
